CN104744356B - 二取代脲类化合物的合成方法 - Google Patents
二取代脲类化合物的合成方法 Download PDFInfo
- Publication number
- CN104744356B CN104744356B CN201510129498.6A CN201510129498A CN104744356B CN 104744356 B CN104744356 B CN 104744356B CN 201510129498 A CN201510129498 A CN 201510129498A CN 104744356 B CN104744356 B CN 104744356B
- Authority
- CN
- China
- Prior art keywords
- crude product
- organic phase
- common salt
- class compound
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- -1 carbamide class compound Chemical class 0.000 title claims abstract description 21
- 238000010189 synthetic method Methods 0.000 title claims abstract description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000006243 chemical reaction Methods 0.000 claims abstract description 33
- 239000012074 organic phase Substances 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 20
- 239000012043 crude product Substances 0.000 claims abstract description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical class CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 11
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 229910021595 Copper(I) iodide Inorganic materials 0.000 claims abstract description 10
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 150000001408 amides Chemical class 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims abstract description 5
- 150000004982 aromatic amines Chemical class 0.000 claims abstract description 3
- 150000001412 amines Chemical class 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Chemical group 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- BMQDAIUNAGXSKR-UHFFFAOYSA-N (3-hydroxy-2,3-dimethylbutan-2-yl)oxyboronic acid Chemical group CC(C)(O)C(C)(C)OB(O)O BMQDAIUNAGXSKR-UHFFFAOYSA-N 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000004809 thin layer chromatography Methods 0.000 abstract description 8
- 238000001035 drying Methods 0.000 abstract description 7
- 239000003054 catalyst Substances 0.000 abstract description 4
- 239000007800 oxidant agent Substances 0.000 abstract description 4
- 230000001590 oxidative effect Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 238000010898 silica gel chromatography Methods 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 53
- 235000013877 carbamide Nutrition 0.000 description 32
- 239000004202 carbamide Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 150000003672 ureas Chemical class 0.000 description 13
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012948 isocyanate Substances 0.000 description 7
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 238000006555 catalytic reaction Methods 0.000 description 6
- 150000002513 isocyanates Chemical class 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VLYURNIAARLUGD-UHFFFAOYSA-N CC(=O)N(C1=CC=C(C=C1)[N+](=O)[O-])C(=O)C2=CC=CC=N2 Chemical class CC(=O)N(C1=CC=C(C=C1)[N+](=O)[O-])C(=O)C2=CC=CC=N2 VLYURNIAARLUGD-UHFFFAOYSA-N 0.000 description 4
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N HOCMe2CMe2OH Natural products CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 3
- 150000002527 isonitriles Chemical class 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- GWEHVDNNLFDJLR-UHFFFAOYSA-N 1,3-diphenylurea Chemical compound C=1C=CC=CC=1NC(=O)NC1=CC=CC=C1 GWEHVDNNLFDJLR-UHFFFAOYSA-N 0.000 description 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical class NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical class NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical class NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 0 [O-][N+](c1ccc(CC(N/C2=*/CC/C=C/C=C2)=O)cc1)=O Chemical compound [O-][N+](c1ccc(CC(N/C2=*/CC/C=C/C=C2)=O)cc1)=O 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940062328 actos Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C273/00—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C273/18—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas
- C07C273/1809—Preparation of urea or its derivatives, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups of substituted ureas with formation of the N-C(O)-N moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
本发明涉及一种二取代脲类化合物的合成方法。该方法的具体步骤为：①在空气气氛下，将酰胺、芳胺、碘化亚铜、1,10‑菲啰啉按1:(1.0～2.0):(0.1～0.2):(0.2～0.4)的摩尔比加入到N,N‑二甲基甲酰胺溶剂中，于110～130 oC下搅拌至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取产物，有机相用饱和食盐水洗涤，经干燥、用旋转蒸发仪除去有机相中的溶剂后得粗产物；③粗产物用硅胶柱层析纯化，展开剂根据薄层层析情况和产物的极性情况选择，即得到相应的二取代脲类化合物。本发明方法原料简单易得，催化剂廉价，使用常规的反应溶剂，以空气为氧化剂。操作简单，产率中等到优秀，在工业生产中有很好的发展前景。
Description
技术领域
本发明涉及一种脲类化合物的合成方法，特别是一种是铜催化下通过碳-碳键活化的二取代脲类化合物的简便合成方法。
背景技术
脲类化合物，因其具有较高的生物活性、生理药理活性，而受到人们的广泛关注。例如，Norvir是一种强效蛋白酶抑制剂，主要用于抗HIV病毒(见参考文献：Debnath，A.K.etal.J.Med.Chem.1999,42,249)。又如，格列吡嗪控释片(Glipizide)适用于治疗II型糖尿病患者的高血糖及其相关症状(见参看文献：Pedersen,J.M.et al.J.Med.Chem.2008,51,3275)。全美2012年度市场前200位畅销药ACTOS中也含有脲的骨架，同样适用于治疗II型糖尿病(见参看文献：Greene,A.S.et al.J.Med.Chem.2012,55,8260)。此外，目前市场较流行的医药化妆品原料芦荟中，其所具消炎、软化角质及迅速愈合伤口的主要功能，得益于其中含有一定量的尿囊素(见参考文献：Sakamoto,A.et al.Plant.Cell.Environ.2014,37,1022)。
除此以外，由于脲类化合物结构上的特殊性，它可以作为重要的有机合成砌块，用于构建结构更加复杂的化合物。例如，邻位卤素取代的芳基脲在碱性条件下发生关环反应，形成咪唑啉酮类化合物(见参考文献：Bolm,C.etal.Org.Lett.2011,13,2876)。又例如，氰基乙酰基取代的脲在金属的催化下形成一类具有消炎作用的2,4-二羰基嘧啶类化合物(见参考文献：Müller,C.E.Heterocycles.2000,53,347)。
文献中报道过的合成脲类化合物的方法主要有以下几种：
(一)异氰酸酯与胺的反应。这是最常见的方法，主要应用于制备二取代脲(见参考文献：Ganachaud,F.Chem.Rev.2013,113,80)。此类方法的缺点是:原料异氰酸酯需要通过复杂的方法制备，异氰酸酯类化合物有强烈刺激性，为剧毒品，且不稳定，容易聚合，需要在低温、无光照条件下存储等。
2005年，Clayden小组报道了先用异氰酸酯与胺形成二取代脲，然后发生N-烷基化反应得到三取代的脲(见参考文献：Clayden,J.Org.Lett.2005,7,3147)。
(二)通过一氧化碳或者二氧化碳与胺在金属的催化下制备脲。此类方法主要得到对称的二取代脲。这类方法的缺点是：需使用昂贵的催化剂或者只能用于合成对称的二取代脲，方法的局限性很大。
2006年，Angelici小组报道了伯胺与一氧化碳和氧气在金催化下反应，得到对称的二取代脲。其机理是在金的催化氧气的氧化下形成异氰酸酯中间体与第二分子的胺反应形成脲(见参考文献：Angelici,R.J.J.Am.Chem.Soc.2006,128,14460)。
2011年，McElwee-White小组报道了伯胺与一氧化碳在钒催化下得到对称的二取代脲(见参考文献：McElwee-White,L.Eur.J.Org.Chem.2011,2011,6261)。
(三)通过异腈在过氧化物或者氮氧化物等强氧化剂条件下，先形成异氰酸酯之后再与胺反应得到。这类方法的缺点是：原料需要多步制备，采用过氧化物为氧化剂比较危险。
2004年，Zakrzewski小组报道了异腈经m-CPBA氧化，然后与二级胺反应得到三取代脲(见参考文献：Zakrzewski,J.Org.Lett.2004,6,695)。
2010年，Ichikawa小组报道了异腈在吡啶氮氧化物作用下生成异氰酸酯，然后与仲胺反应生成三取代脲(见参考文献：Ichikawa，J.J.Org.Chem.2010,2010,6331)
(四)Ukaji小组报道了二羰基咪唑与伯胺在水中反应可以得到对称的二取代脲和非对称的三取代脲(见参考文献：Padiya,K.J.Org.Lett.2012,14,2814)。
综上所述，脲类化合物的合成方法有以上几种，但是这些反应的底物都相对较为复杂，毒性较大，活着使用昂贵的金属作为催化剂，或者经过多步反应才能得到产物。
发明内容
本发明的目的在于提供一种二取代脲类化合物的合成方法。
为达到上述目的，本发明方法采用的反应机理为：
一种二取代脲类化合物的合成方法，其特征在于该方法具有如下步骤：将酰胺、芳胺、碘化亚铜、1,10-菲啰啉按1:(1.0～2.0):(0.1～0.2):(0.2～0.4)的摩尔比加入到N,N-二甲基甲酰胺溶剂中，于110～130℃下搅拌至反应原料消失；反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取产物，有机相用饱和食盐水洗涤，除去溶剂后得粗产物；该粗产物经分离纯化得到二取代脲类化合物，其结构式为：所述的酰胺的结构式为：所述的芳胺的结构式为：其中：R＝氢、氟、氯、溴、甲氧基、-硼酸频哪醇酯，其中：X＝N，CH-。
本发明的二取代脲类化合物是一类重要的有机反应中间体，通过不同类型的有机化学反应，如催化加一氧化碳环化(见参考文献：Matthias，B.Angew.Chem.Int.Ed.1999,38,1454)、脱水反应(见参考文献：Palomo,C.Synthesis,1981,5,373)、付克酰基化反应，N-烷基化反应等，可方便、快捷地合成出一系列的多取代脲，环状脲的衍生物,以及二亚胺类化合物。
本发明方法采用对硝基苯乙酰苯基(吡啶)酰胺为反应原料简单易得，催化剂廉价，使用常规的反应溶剂，以空气为氧化剂。操作简单，产率中等到优秀，在工业生产中有很好的发展前景。
具体实施方式
实施例一：N-苯基-N’-(2-吡啶基)脲
N-苯基-N’-(2-吡啶基)脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰2-吡啶酰胺，苯胺10毫升，碘化亚铜1.9克，1,10-菲啰啉3.6克，N,N-二甲基甲酰胺200毫升，加热至120℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析梯度洗脱(石油醚:乙酸乙酯＝1:5至1:3)纯化，得到N-苯基-N’-(2-吡啶基)脲15.8克，产率为74％。
1H NMR(DMSO-d6,500MHz):δ10.47(s,1H),9.40(s,1H),8.25-8.22(m,1H),7.72-7.69(m,1H),7.49-7.46(m,3H),7.28-7.26(m,2H),7.01-6.96(m,2H)；
13C NMR(DMSO-d6,125MHz):δ152.9,152.2,146.9,139.0,138.6,128.9,122.5118.8；
LC-MS(ESI)m/z:213[M+Na].
实施例二：N-(4-溴苯基)-N’-(2-吡啶基)脲
N-(4-溴苯基)-N’-(2-吡啶基)脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰2-吡啶酰胺，4-溴苯胺25克，碘化亚铜1.9克，1,10-菲啰啉3.6克，N,N-二甲基甲酰胺200毫升，加热至120℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析(石油醚:乙酸乙酯＝1:5)纯化，得到N-(4-溴苯基)-N’-(2-吡啶基)脲17.5克，产率为60％。
1H NMR(DMSO-d6,500MHz):δ10.65(s,1H),9.50(s,1H),8.27(td,J＝7.5,2.0Hz,1H),7.55-7.45(m,5H)；
13C NMR(DMSO-d6,125MHz):δ153.1,152.5,147.3,139.0,138.9,132.0,121.2,118.0,114.4,112.4；
LC-MS(ESI)m/z:291[M+Na].
实施例三：N-(4-氯苯基)-N’-(2-吡啶基)脲
N-(4-氯苯基)-N’-(2-吡啶基)脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰2-吡啶酰胺，4-氯苯胺25.4毫升，碘化亚铜3.8克，1,10-菲啰啉7.2克，N,N-二甲基甲酰胺200毫升，加热至110℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析(石油醚:乙酸乙酯＝1:5)纯化，得到N-(4-氯苯基)-N’-(2-吡啶基)脲15.3克，产率为62％。
1H NMR(DMSO-d6,500MHz):δ10.65(s,1H),9.49(s,1H),8.29-8.26(m,1H),7.77-7.73(m,1H),7.58-7.54(m,2H),7.47(d,J＝8.0Hz,1H),7.39-7.33(m,2H),7.04-6.98(m,1H)；
13C NMR(DMSO-d6,125MHz):δ152.7,152.1,146.9,138.6,138.0,128.7,126.0120.3,117.6,111.9；
LC-MS(ESI)m/z:247[M+Na].
实施例四：N-(4-氟苯基)-N’-(2-吡啶基)脲
N-(4-氟苯基)-N’-(2-吡啶基)脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰2-吡啶酰胺，4-氟苯胺14.5克，碘化亚铜2.5克，1,10-菲啰啉4.7克，N,N-二甲基甲酰胺200毫升，加热至130℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析(石油醚:乙酸乙酯＝1:5)纯化，得到N-(4-氟苯基)-N’-(2-吡啶基)脲16.9克，产率为73％。
1H NMR(DMSO-d6,500MHz):δ10.57(s,1H),9.44(s,1H),8.30-8.25(m,1H),7.77-7.71(m,1H),7.58-7.52(m,2H),7.46(d,J＝8.0Hz,1H),7.15(t,J＝9.0Hz,2H),7.00(m,1H)；
13C NMR(DMSO-d6,125MHz):δ158.6,156.7,152.8,152.2,146.8,138.5,135.3,120.6,117.4,115.4,115.2,111.9；
LC-MS(ESI)m/z:231[M+Na].
实施例五：N-(4-硼酸频哪醇酯-苯基)-N’-(2-吡啶基)脲
N-(4-硼酸频哪醇酯-苯基)-N’-(2-吡啶基)脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰2-吡啶酰胺，4-硼酸频哪醇酯-苯胺26.3毫升，碘化亚铜2.3克，1,10-菲啰啉4.4克，N,N-二甲基甲酰胺200毫升，加热至110℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析梯度洗脱(石油醚:乙酸乙酯＝1:5至1:3)纯化，得到N-(4-硼酸频哪醇酯-苯基)-N’-(2-吡啶基)脲21.8克，产率为64％。
1H NMR(DMSO-d6,500MHz):δ10.70(s,1H),9.53(s,1H),8.31-8.28(m,1H),7.78-7.73(m,1H),7.65-7.60(m,2H),7.58-7.53(m,2H),7.51-7.46(m,1H),7.04-7.00(m,1H),1.28(s,12H)；
13C NMR(DMSO-d6,125MHz):δ152.7,152.0,146.9,142.0,138.6,135.5,117.7,117.6,111.9,83.4,24.7；
LC-MS(ESI)m/z:341[M+Na].
实施例六：N-苯基-N’-苯基脲
N-苯基-N’-苯基脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰苯胺酰胺，苯胺10毫升，碘化亚铜2.85克，1,10-菲啰啉5.4克，N,N-二甲基甲酰胺200毫升，加热至120℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析梯度洗脱(石油醚:乙酸乙酯＝1:5至1:3)纯化，得到N-苯基-N’-苯基脲11.7克，产率为55％。
1H NMR(DMSO-d6,500MHz):δ8.65(s,2H),7.45(d,J＝7.5Hz 1H),7.28(t,J＝8.0Hz,4H),6.96(t,J＝8.0Hz,2H)；
13C NMR(DMSO-d6,125MHz):δ152.5,139.7,128.7,121.8,118.1；
LC-MS(ESI)m/z:212[M+Na].
实施例七：N-(4-甲氧基苯基)-N’-苯基脲
N-(4-甲氧基苯基)-N’-苯基脲采用下述步骤：①在250毫升反应釜中加入25.7克对硝基苯乙酰苯胺酰胺，对甲氧基苯胺14克，碘化亚铜2.0克，1,10-菲啰啉4.0克，N,N-二甲基甲酰胺200毫升，加热至120℃。用薄层层析方法跟踪反应，至反应原料消失；②反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取，合并有机相，有机相用饱和食盐水洗涤，有机相经干燥后去除溶剂后得粗产物；③粗产物用柱层析梯度洗脱(石油醚:乙酸乙酯＝1:5至1:3)纯化，得到N-(4-甲氧基苯基)-N’-苯基脲22.7克，产率为94％。
1H NMR(DMSO-d6,500MHz):δ10.40(s,1H),9.38(s,1H),8.28-8.24(m,1H),7.75-7.69(m,1H),7.47-7.40(m,3H),7.01-6.96(m,1H),6.92-6.86(m,2H),3.72(s,3H)；
13C NMR(DMSO-d6,125MHz):δ154.9,153.0,152.3,146.8,138.4,132.0,120.6,117.2,114.0,111.8,55.2；
LC-MS(ESI)m/z:242[M+Na]。
Claims (1)
1.一种二取代脲类化合物的合成方法，其特征在于该方法具有如下步骤：将酰胺、芳胺、碘化亚铜、1,10-菲啰啉按1:(1.0～2.0):(0.1～0.2):(0.2～0.4)的摩尔比加入到N,N-二甲基甲酰胺溶剂中，于110～130℃下搅拌至反应原料消失；反应结束后，体系中加入过量的饱和食盐水，用乙酸乙酯萃取产物，有机相用饱和食盐水洗涤，除去溶剂后得粗产物；该粗产物经分离纯化得到二取代脲类化合物，其结构式为：所述的酰胺的结构式为：所述的芳胺的结构式为：其中：R＝氢、氟、氯、溴、甲氧基、硼酸频哪醇酯，其中：X＝N，CH。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510129498.6A CN104744356B (zh) | 2015-03-24 | 2015-03-24 | 二取代脲类化合物的合成方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510129498.6A CN104744356B (zh) | 2015-03-24 | 2015-03-24 | 二取代脲类化合物的合成方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104744356A CN104744356A (zh) | 2015-07-01 |
| CN104744356B true CN104744356B (zh) | 2017-05-31 |
Family
ID=53584708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510129498.6A Expired - Fee Related CN104744356B (zh) | 2015-03-24 | 2015-03-24 | 二取代脲类化合物的合成方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104744356B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106316891A (zh) * | 2016-08-23 | 2017-01-11 | 岳姗姗 | 一种阿托伐他汀钙中间体杂质及其制备方法 |
| CN109776244A (zh) * | 2019-01-28 | 2019-05-21 | 浙江大学 | 一种脲类化合物的合成方法及应用 |
| CN114014803B (zh) * | 2021-10-27 | 2023-11-10 | 内蒙古师范大学 | 一种室温下利用酰胺与胺的酰胺化反应合成尿素类化合物的方法 |
| CN113861108B (zh) * | 2021-10-27 | 2023-11-10 | 内蒙古师范大学 | 一种室温下利用酰胺与醇的酯化反应合成氨基甲酸酯类化合物的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045921A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
-
2015
- 2015-03-24 CN CN201510129498.6A patent/CN104744356B/zh not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003045921A1 (en) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic amide compounds as apolipoprotein b inhibitors |
Non-Patent Citations (5)
| Title |
|---|
| Acetoacetanilides as Masked Isocyanates: Facile and Efficient Synthesis of Unsymmetrically Substituted Ureas;Ying Wei等;《ORGANIC LETTERS》;20100901;第12卷(第19期);第4220-4223页 * |
| -Dialkylureas.《J. Org. Chem.》.1999,第64卷(第3期),第1004-1006页. * |
| Franca Bigi等.Reaction of Aliphatic Amines with Acetoacetanilide in the Presence of Zeolite Catalyst. Solvent-Free Synthesis of Symmetric N,N¢ * |
| Synthesis of Unsymmetrical 2-Pyridyl Ureas via Selenium-Catalyzed Oxidative Carbonylation of 2-Aminopyridine with Aromatic Amines;Xiaopeng Zhang等;《SYNTHESIS》;20130425;第45卷(第10期);第1357–1363页 * |
| 微波固态合成N-芳杂环-N′-芳基脲类化合物的研究;孙婷等;《化学世界》;20081231(第1期);第46-48页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104744356A (zh) | 2015-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104744356B (zh) | 二取代脲类化合物的合成方法 | |
| EP3572401B1 (en) | Ask1 inhibitor and preparation method and use thereof | |
| CN105820110B (zh) | 匹莫范色林合成方法 | |
| EP3279188B1 (en) | Axially chiral isomers, and preparation methods therefor and pharmaceutical uses thereof | |
| CN101781269B (zh) | 4-叔丁基-2-(硝基苄亚氨基)噻唑衍生物及其制备方法与应用 | |
| CA2411082A1 (en) | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament | |
| EP2985277B1 (en) | Method for preparing an atropisomer of a pyrrole derivative | |
| CA2903737A1 (en) | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor | |
| CN102985416A (zh) | 制备凝血酶特异性抑制剂的方法 | |
| CN103214487A (zh) | 一种重要医药化工原料(6s)-5-甲基四氢叶酸盐的合成 | |
| CN105481856B (zh) | 一种帕利哌酮的制备方法 | |
| CN101302207B (zh) | 3-ο-烷基-5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法以及5,6-ο-(1-甲基乙叉基)-l-抗坏血酸的制造方法 | |
| CN103497146B (zh) | 2-(n-芳甲基哌啶-4-氨基)-4-(取代苯酚)苯环衍生物及其制备方法与应用 | |
| ES2211061T3 (es) | Derivados piridinicos que inhiben pde iv. | |
| WO2014020381A1 (en) | Novel crystalline form of azilsartan medoxomil potassium | |
| EP3674304B1 (en) | Crystal form of parp-1 inhibitor and preparation method therefor | |
| AU2021297767A1 (en) | Preparation method for aromatic ether compound | |
| CN102464660A (zh) | 6-(4-氯苯基)-2,2-二甲基-7-苯基-2,3-二氢基-吡咯哩嗪-5-乙酸硝酸丁酯晶体及其制备方法和应用 | |
| CN105777616B (zh) | 色瑞替尼的合成中间体及其制备方法 | |
| CN102516159A (zh) | 一种苯磺酸左旋氨氯地平的生产方法 | |
| CN105669649B (zh) | 一种埃索美拉唑及其盐的制备方法 | |
| CN106518751B (zh) | 一种制备匹莫范色林的方法 | |
| WO2023082145A1 (en) | Intermediate compound of quinoxaline and preparation process thereof | |
| CN115403515B (zh) | 吡仑帕奈降解杂质的制备方法及其应用 | |
| JPH0413666A (ja) | １―（アルコキシフェニル）―３―（４，５，６，７―テトラヒドロベンズイミダゾリル）ウレア |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170531 Termination date: 20200324 |